CAS: 64695-78-9; 1,2-Dibromo-4,5-Difluorobenzene

上下游产品

CAS号367-11-3 邻二氟苯 | CAS号1312175-89-5 3-[4,5-difluoro... | CAS号3031-68-3 2,4-己二炔-1,6-二醇 | CAS号134450-56-9 4,5-二氟酞腈 | CAS号175883-15-5 1,2-difluoro-4-... | CAS号5929-72-6 2,7-二甲基-3,5-辛二炔... | CAS号1312175-90-8 4-[4,5-difluoro...

1,2-二氟苯置于溴,铁粉体系中,化学反应生成 1,2-二溴-4,5-二氟苯
参考文献:Fluorinated Tricyclic Neuroleptics: 6,7-Difluoro Derivative Of Chlorprothixene And 2-Fluoro-3-Hydroxy Derivative Of octoclothepin
标题:Fluorinated Tricyclic Neuroleptics: 6,7-Difluoro Derivative Of Chlorprothixene And 2-Fluoro-3-Hydroxy Derivative Of octoclothepin
摘要:
DOI:10.1135/cccc19772001

专利信息

专利号:US-7658868-B2
优先权日:2002-03-20
标 题 :Molecular actuators, and methods of use thereof
发明人：ANQUETIL PATRICK A; HUNTER IAN W; MADDEN JOHN D; MADDEN PETER G; PULLEN ANTHONY E; SWAGER TIMOTHY M; XU BING; YU HSIAO-HUA
权利人:MASSACHUSETTS INST TECHNOLOGY; US NAVY
摘要:The synthesis of thiophene based conducting polymer molecular actuators, exhibiting electrically triggered molecular conformational transitions is reported. Actuation is believed to be the result of conformational rearrangement of the polymer backbone at the molecular level, not simply ion intercalation in the bulk polymer chain upon electrochemical activation. Molecular actuation results from Ï€-Ï€ stacking of thiophene oligomers upon oxidation, producing a reversible molecular displacement that leads to surprising material properties, such as electrically controllable porosity and large strains. The existence of active molecular conformational changes is supported by in situ electrochemical data. Single molecule techniques have been used to characterize the molecular actuators.

专利号:US-9067934-B2
优先权日:2011-03-31
标题 :Bicyclic pyridinones
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; FISH BENJAMIN ADAM; GREEN MICHAEL ERIC; MULLINS PATRICK BRADLEY; STIFF CORY MICHAEL; TRAN TUAN PHONG; NAVARATNAM THAYALAN
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.